- Graham Kyle, consultant ophthalmologist1
- 1Liverpool L1 9AR, UK
- grahamkyle33{at}gmail.com
Jackson and Kirkpatrick recommend adopting cheaper bevacizumab over more expensive ranibizumab to treat wet age related macular degeneration.1 However, their cost projections “do not consider any potential differences in safety, medicolegal risk, treatment burden, or patient preference . . . .”
The medicolegal risks of such an adoption are considerable, not least for …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.